Goldman Sachs reported fourth-quarter earnings of $5.68 a share that topped Wall Street estimates, but shares edged lower in premarket trading. » Read More
Jim Cramer spoke to Alkermes CEO Richard Pops, who said 2018 will be a year of milestones for his company's drugs.
BioMarin's Jean-Jacques Bienaime believes the company's hemophilia treatment could fundamentally change the quality of life for patients.
Atlantic City's most spectacular casino flop is getting another chance under new ownership and a new name.
The full interview with Incyte CEO Hervé Hoppenot at J.P. Morgan Health in San Francisco.
Liulishuo employs deep learning to create personalized English courses powered by AI.
Infants in America are 76 percent more likely to die before age 1 than counterparts in other wealthy countries.
Royce is in his last year as committee chairman, because Republicans in Congress set term limits on committee leadership.
Mark Zuckerberg, Jan Koum and other top Facebook execs sold more than $4 billion in stock last year.
The deal would have helped Huawei break into the U.S. market.
The position became vacant in October after veteran central banker Stanley Fischer stepped down for personal reasons.
A new Silicon Valley craze could make people sick.
Twitter users were upset by a museum plaque that seemed to be spreading misinformation about climate change, the Verge reports.
BioMarin CEO Jean-Jacques Bienaime discusses the company's hemophilia A treatment at J.P. Morgan Health in San Francisco.
Amazon just rolled out Alexa Onboard, a new voice control system for your car that works even when you're offline.
Shares of a Hong Kong-based crypto company have been halted after soaring last year, as the U.S. cites concerns about unusual activity.
Toyota unveiled a new take on the "mobility" concept at CES on Monday.
Digital currencies fall broadly, with ripple and bitcoin leading the charge lower.
Visa said it will boost contributions to employees' retirement benefits, citing tax reform.
UBS reiterates its buy rating on Apple shares, predicting the tax reform law will free up funds for the company’s stock buyback program.
Shire ditched its revenue target of $20 billion by 2020 due to increased generic competition and new drugs from rivals.